PKHD1L1
Fibrocystin-L
Also known as: PKHL1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q86WI1
- Gene
- PKHD1L1
- Ensembl
- ENSG00000205038
- Chromosome
- 8
- Canonical length
- 4243 aa
- Protein class
- Predicted membrane proteins
- Subcellular location
- Flagellar centriole,Mid piece,Principal piece
OverviewNCBI Gene
Predicted to enable signaling receptor activity. Predicted to be involved in immune response. Predicted to act upstream of or within sensory perception of sound. Predicted to be located in cytosol; extracellular space; and membrane. Implicated in autosomal recessive nonsyndromic deafness. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
4243 residues, UniProt reviewed canonical sequence.
>Q86WI1|PKHD1L1
1 MGHLWLLGIW GLCGLLLCAA DPSTDGSQII PKVTEIIPKY GSINGATRLT IRGEGFSQAN
61 QFNYGVDNAE LGNSVQLISS FQSITCDVEK DASHSTQITC YTRAMPEDSY TVRVSVDGVP
121 VTENNTCKGH INSWECTFNA KSFRTPTIRS ITPLSGTPGT LITIQGRIFT DVYGSNIALS
181 SNGKNVRILR VYIGGMPCEL LIPQSDNLYG LKLDHPNGDM GSMVCKTTGT FIGHHNVSFI
241 LDNDYGRSFP QKMAYFVSSL NKIAMFQTYA EVTMIFPSQG SIRGGTTLTI SGRFFDQTDF
301 PVRVLVGGEP CDILNVTENS ICCKTPPKPH ILKTVYPGGR GLKLEVWNNS RPIRLEEILE
361 YNEKTPGYMG ASWVDSASYI WLMEQDTFVA RFSGFLVAPD SDVYRFYIKG DDRYAIYFSQ
421 TGLPEDKVRI AYHSANANSY FSSPTQRSDD IHLQKGKEYY IEILLQEYRL SAFVDVGLYQ
481 YRNVYTEQQT GDAVNEEQVI KSQSTILQEV QVITLENWET TNAINEVQKI KVTSPCVEAN
541 SCSLYQYRLI YNMEKTVFLP ADASEFILQS ALNDLWSIKP DTVQVIRTQN PQSYVYMVTF
601 ISTRGDFDLL GYEVVEGNNV TLDITEQTKG KPNLETFTLN WDGIASKPLT LWSSEAEFQG
661 AVEEMVSTKC PPQIANFEEG FVVKYFRDYE TDFNLEHINR GQKTAETDAY CGRYSLKNPA
721 VLFDSADVKP NRRPYGDILL FPYNQLCLAY KGFLANYIGL KFQYQDNSKI TRSTDTQFTY
781 NFAYGNNWTY TCIDLLDLVR TKYTGTNVSL QRISLHKASE SQSFYVDVVY IGHTSTISTL
841 DEMPKRRLPA LANKGIFLEH FQVNQTKTNG PTMTNQYSVT MTSYNCSYNI PMMAVSFGQI
901 ITHETENEFV YRGNNWPGES KIHIQRIQAA SPPLSGSFDI QAYGHILKGL PAAVSAADLQ
961 FALQSLEGMG RISVTREGTC AGYAWNIKWR STCGKQNLLQ INDSNIIGEK ANMTVTRIKE
1021 GGLFRQHVLG DLLRTPSQQP QVEVYVNGIP AKCSGDCGFT WDSNITPLVL AISPSQGSYE
1081 EGTILTIVGS GFSPSSAVTV SVGPVGCSLL SVDEKELKCQ ILNGSAGHAP VAVSMADVGL
1141 AQNVGGEEFY FVYQSQISHI WPDSGSIAGG TLLTLSGFGF NENSKVLVGN ETCNVIEGDL
1201 NRITCRTPKK TEGTVDISVT TNGFQATARD AFSYNCLQTP IITDFSPKVR TILGEVNLTI
1261 KGYNFGNELT QNMAVYVGGK TCQILHWNFT DIRCLLPKLS PGKHDIYVEV RNWGFASTRD
1321 KLNSSIQYVL EVTSMFPQRG SLFGGTEITI RGFGFSTIPA ENTVLLGSIP CNVTSSSENV
1381 IKCILHSTGN IFRITNNGKD SVHGLGYAWS PPVLNVSVGD TVAWHWQTHP FLRGIGYRIF
1441 SVSSPGSVIY DGKGFTSGRQ KSTSGSFSYQ FTSPGIHYYS SGYVDEAHSI FLQGVINVLP
1501 AETRHIPLHL FVGRSEATYA YGGPENLHLG SSVAGCLATE PLCSLNNTRV KNSKRLLFEV
1561 SSCFSPSISN ITPSTGTVNE LITIIGHGFS NLPWANKVTI GSYPCVVEES SEDSITCHID
1621 PQNSMDVGIR ETVTLTVYNL GTAINTLSNE FDRRFVLLPN IDLVLPNAGS TTGMTSVTIK
1681 GSGFAVSSAG VKVLMGHFPC KVLSVNYTAI ECETSPAAQQ LVDVDLLIHG VPAQCQGNCT
1741 FSYLESITPY ITGVFPNSVI GSVKVLIEGE GLGTVLEDIA VFIGNQQFRA IEVNENNITA
1801 LVTPLPVGHH SVSVVVGSKG LALGNLTVSS PPVASLSPTS GSIGGGTTLV ITGNGFYPGN
1861 TTVTIGDEPC QIISINPNEV YCRTPAGTTG MVDVKIFVNT IAYPPLLFTY ALEDTPFLRG
1921 IIPSRGPPGT EIEITGSNFG FEILEISVMI NNIQCNVTMA NDSVVQCIVG DHAGGTFPVM
1981 MHHKTKGSAM STVVFEYPLN IQNINPSQGS FGGGQTMTVT GTGFNPQNSI ILVCGSECAI
2041 DRLRSDYTTL LCEIPSNNGT GAEQACEVSV VNGKDLSQSM TPFTYAVSLT PLITAVSPKR
2101 GSTAGGTRLT VVGSGFSENM EDVHITIAEA KCDVEYSNKT HIICMTDAHT LSGWAPVCVH
2161 IRGVGMAKLD NADFLYVDAW SSNFSWGGKS PPEEGSLVVI TKGQTILLDQ STPILKMLLI
2221 QGGTLIFDEA DIELQAENIL ITDGGVLQIG TETSPFQHKA VITLHGHLRS PELPVYGAKT
2281 LAVREGILDL HGVPVPVTWT RLAHTAKAGE RILILQEAVT WKPGDNIVIA STGHRHSQGE
2341 NEKMTIASVS ADGINITLSN PLNYTHLGIT VTLPDGTLFE ARAEVGILTR NILIRGSDNV
2401 EWNNKIPACP DGFDTGEFAT QTCLQGKFGE EIGSDQFGGC VMFHAPVPGA NMVTGRIEYV
2461 EVFHAGQAFR LGRYPIHWHL LGDLQFKSYV RGCAIHQAYN RAVTIHNTHH LLVERNIIYD
2521 IKGGAFFIED GIEHGNILQY NLAVFVQQST SLLNDDVTPA AFWVTNPNNT IRHNAVAGGT
2581 HFGFWYRMNN HPDGPSYDRN ICQKRVPLGE FFNNTVHSQG WFGMWIFEEY FPMQTGSCTS
2641 TVPAPAIFNS LTTWNCQKGA EWVNGGALQF HNFVMVNNYE AGIETKRILA PYVGGWGETN
2701 GAVIKNAKIV GHLDELGMGS AFCTAKGLVL PFSEGLTVSS VHFMNFDRPN CVALGVTSIS
2761 GVCNDRCGGW SAKFVDVQYS HTPNKAGFRW EHEMVMIDVD GSLTGHKGHT VIPHSSLLDP
2821 SHCTQEAEWS IGFPGSVCDA SVSFHRLAFN QPSPVSLLEK DVVLSDSFGT SIIPFQKKRL
2881 THMSGWMALI PNANHINWYF KGVDHITNIS YTSTFYGFKE EDYVIISHNF TQNPDMFNII
2941 DMRNGSSNPL NWNTSKNGDW HLEANTSTLY YLVSGRNDLH QSQLISGNLD PDVKDVVINF
3001 QAYCCILQDC FPVHPPSRKP IPKKRPATYN LWSNDSFWQS SRENNYTVPH PGANVIIPEG
3061 TWIVADIDMP SMERLIIWGV LELEDKYNVG AAESSYREVV LNATYISLQG GRLIGGWEDN
3121 PFKGDLKIVL RGNHTTQDWA LPEGPNQGAK VLGVFGELDL HGIPHSIYKT KLSETAFAGS
3181 KVLSLMDAVD WQEGEEIVIT TTSYDFHQTE TRSIVKILHD HKILILNDSL SYTHFAEKYH
3241 VPGTGESYTL AADVGILSRN IKIVGEDYPG WSEDSFGARV LVGSFTENMM TFKGNARISN
3301 VEFYHSGQEG FRDSTDPRYA VTFLNLGQIQ EHGSSYIRGC AFHHGFSPAI GVFGTDGLDI
3361 DDNIIHFTVG EGIRIWGNAN RVRGNLIALS VWPGTYQNRK DLSSTLWHAA IEINRGTNTV
3421 LQNNVVAGFG RAGYRIDGEP CPGQFNPVEK WFDNEAHGGL YGIYMNQDGL PGCSLIQGFT
3481 IWTCWDYGIY FQTTESVHIY NVTLVDNGMA IFPMIYMPAA ISHKISSKNV QIKSSLIVGS
3541 SPGFNCSDVL TNDDPNIELT AAHRSPRSPS GGRSGICWPT FASAHNMAPR KPHAGIMSYN
3601 AISGLLDISG STFVGFKNVC SGETNVIFIT NPLNEDLQHP IHVKNIKLVD TTEQSKIFIH
3661 RPDISKVNPS DCVDMVCDAK RKSFLRDIDG SFLGNAGSVI PQAEYEWDGN SQVGIGDYRI
3721 PKAMLTFLNG SRIPVTEKAP HKGIIRDSTC KYLPEWQSYQ CFGMEYAMMV IESLDPDTET
3781 RRLSPVAIMG NGYVDLINGP QDHGWCAGYT CQRRLSLFHS IVALNKSYEV YFTGTSPQNL
3841 RLMLLNVDHN KAVLVGIFFS TLQRLDVYVN NLLVCPKTTI WNAQQKHCEL NNHLYKDQFL
3901 PNLDSTVLGE NYFDGTYQML YLLVKGTIPV EIHTATVIFV SFQLSVATED DFYTSHNLVK
3961 NLALFLKIPS DKIRISKIRG KSLRRKRSMG FIIEIEIGDP PIQFISNGTT GQMQLSELQE
4021 IAGSLGQAVI LGNISSILGF NISSMSITNP LPSPSDSGWI KVTAQPVERS AFPVHHVAFV
4081 SSLLVITQPV AAQPGQPFPQ QPSVKATDSD GNCVSVGITA LTLRAILKDS NNNQVNGLSG
4141 NTTIPFSSCW ANYTDLTPLR TGKNYKIEFI LDNVVGVESR TFSLLAESVS SSGSSSSSNS
4201 KASTVGTYAQ IMTVVISCLV GRMWLLEIFM AAVSTLNITL RSYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PKHD1L1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0
- Highest tissue expression
- 61 nTPM
Expression across tissuesHPA
Tissue
- thyroid gland: 61 nTPM
- adipose tissue: 22 nTPM
- fallopian tube: 15 nTPM
- cervix: 13 nTPM
- heart muscle: 8 nTPM
- lung: 6 nTPM
Single-cell type
- lymphatic endothelial cells: 1,442 nCPM
- mesothelial cells: 1,322 nCPM
- epicardial cells: 1,237 nCPM
- platelets: 504 nCPM
- fallopian secretory cells: 237 nCPM
- endometrial ciliated cells: 202 nCPM
Immune cell
- memory B-cell: 0.4 nTPM
- naive B-cell: 0.3 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
Brain region
- choroid plexus: 3 nTPM
- white matter: 0.8 nTPM
- hypothalamus: 0.5 nTPM
- amygdala: 0.4 nTPM
- basal ganglia: 0.3 nTPM
- cerebral cortex: 0.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PKHD1L1.
Disease | AllUniProt
Conditions PKHD1L1 is implicated in, by any mechanism.
- Deafness, autosomal recessive, 124 (DFNB124) MIM:620794
Disease | GeneticClinVar
21 pathogenic / likely-pathogenic of 755 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Autosomal recessive nonsyndromic hearing loss 124
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.06
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.72
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PKHD1L1 as an antibody target. Whether an autoantibody or antibody against PKHD1L1 could matter depends on whether native PKHD1L1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PKHD1L1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PKHD1L1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...